Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

INTRODUCTION: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables, would be very useful for clinical practice. The aim of this study was to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Lees, Charlie W., Deuring, J. Jasper, Chiorean, Michael, Daperno, Marco, Bonfanti, Gianluca, Germino, Rebecca, Brown, Pritha Bhadra, Modesto, Irene, Edwards, Roger A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832332/
https://www.ncbi.nlm.nih.gov/pubmed/35154388
http://dx.doi.org/10.1177/17562848211054710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832332/
https://www.ncbi.nlm.nih.gov/pubmed/35154388
http://dx.doi.org/10.1177/17562848211054710

Ejemplares similares